Target-based ADME/ Tox Assay Market Overview
The term ADME is an abbreviation in pharmacokinetics and pharmacology it stands for absorption, distribution, digestion and Excretion. It describes the nature of pharmaceutical compounds within the organism. These four criteria are essential for the kinetics of drug subjection at the tissue level hence, drug testing for target-based ADME/ tox assay is decision making test for the development of drugs.
Target-based ADME/ tox assay also test how fast the drug enters and clear from the body. It is used to test what chemical forms it takes, once it is metabolized, and whether there any other actions other than what it was designed to do (adverse effect).
Target-based ADME/ tox assay is widely accepted by biotechnology and pharmaceutical industries to diminish their medication exposure, testing and advancement cost. The Target-based ADME/ tox assay market is classified into 3 main type in-silico testing, in-vitro and in-vivo testing. In-vitro testing is further grouped onto biochemical and cell such as liver, intestinal and kidney based examines.
Target-Based ADME/ Tox Assay Market: Drivers and Restraints
Rising application of Target-based ADME/ tox assay by pharmaceutical and biotechnology companies due to reduction in costs involved in various tests during the development of drugs will be the major driver for this market.
Moreo0ver, increase in necessity for novel drug molecules, reduction in the number of drugs failure and technological advancement such as use of silico technology that uses computer based testing techniques for better and faster result will further contribute to boost the market for target-based ADME/ tox assay market over the forecast period.
However, high installation and maintenance cost will impede the market growth over the coming years. Additionally, factors such as, lack of in-vitro models to identify autoimmunity and immune stimulation will hamper the market growth over the forecast period.
Target-Based ADME/ Tox Assay Market: Overview
The global target-based ADME/ tox assay market is expected to grow exponentially over the forecast period due to increase in number Pharmaceutical and Biotechnology industries worldwide. The market is supposed to grow with high rate due to the development of technologically advanced techniques and an increasing consumer preference.
Target-based ADME/ tox assay market has given the robust growth opportunity to the top biopharmaceutical companies. According to the data, in 2017 43% of ADME toxicology testing areas carried out were based on cell culture technology. By end user. Biopharmaceutical companies are expected to hold the major revenue over the forecast period.
Target-Based ADME/ Tox Assay Market: Regional Overview
North America is expected to hold the largest revenue share for global target-based ADME/ tox assay market over the forecast period due to acceptance of technologically advanced device and more number of R&D. After North America, Europe is expected to be the next revenue generating market due to same reason.
Asian Countries like India and China is expected to show a fastest growth due to increasing government initiatives and collaboration with the foreign pharmaceuticals and Research companies. Middle East and African will show a least lucrative growth due to lack of health infrastructure in these region.
Target-Based ADME/ Tox Assay Market: Key Players
Some of the major key players operating at the global level for target-based ADME/ tox assay market are Accelrys, Inc., Beckman Coulter, Inc., Caliper Life Sciences, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Cyprotex PLC., Cellartis AB, Life Technologies Corporation, Optivia Biotechnology, Inc., MultiCASE, Inc., Xceleron, Inc., ACEA Biosciences, Inc., CeeTox, Inc., Promega Corporation, Thermo Fisher Scientific, Inc. and others.
The research report on target-based ADME/ tox assay market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies.
The research report on target-based ADME/ tox assay market provides analysis and information according to market segments such as geographies, application, and industry.
The report covers exhaust analysis on Target-Based ADME/ Tox Assay market
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Report on Target-Based ADME/ Tox Assay market includes regional analysis
- North America (U.S., Canada)
- Latin America (Mexico, Brazil)
- Europe (Germany, Italy, France, U.K, Spain, Russia)
- East Asia (China, Japan, South Korea)
- South Asia (India, ASEAN)
- Oceania (Australia, New Zealand)
- Middle East and Africa (GCC Countries, South Africa, Northern Africa)
The report on target-based ADME/ tox assay market is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Target-Based ADME/ Tox Assay Market: Segmentation
The global target-based ADME/ Tox Assay market is classified on the basis of method, technology, application, end user and region.
Based on method, target-based ADME/ tox assay market is segmented into the following:
- Cellular Assay
- Biochemical Assay
- In-Silico Assays
- Ex-vivo Assays
Based on technology, target-based ADME/ tox assay market is segmented into the following:
- Cell Culture
- High Throughput
- Molecular Imaging
- OMICS Technology
Based on application, target-based ADME/ tox assay market is segmented into the following:
- Systematic toxicity
- Renal toxicity
Based on end user, target-based ADME/ tox assay market is segmented into the following:
- Biopharmaceutical Companies
- Contract Research Organization ( CRO’s)
- Academic and Research Institute